We do have debt on our balance sheet. As far as interest rates, we re protected somewhat because we ve got long-term bonds. The short-term interest rates do affect us, however, we are paying down the floating debt at a pretty good clip. Those are the short-term things. Longer term, I worry a little bit about any healthcare reform affecting our business directly on the diagnostic side or affecting our pharmaceutical customers on the life science research side.
Reform can get pretty arbitrary country by country.
The good thing with healthcare reform is that it doesn t happen in every country all at the same time. So global reach is important. So we re not in bad shape from a global standpoint. The one place where we have been spending a lot of strategic time is in China. We have a very successful business in China.